Genmab (Otc) ((GMAB)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab has initiated a Phase 1/2 clinical study titled ‘A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors.’ The study aims to assess the safety, tolerability, pharmacokinetics, anti-tumor activity, and immunogenic potential of GEN1286 in individuals with advanced solid tumors. This research is significant as it could lead to new treatment options for patients with limited alternatives.
The intervention being tested is GEN1286, a drug designed to target and treat advanced solid tumors. The study will explore different doses and their effects on tumor-specific cohorts.
The study design involves two parts: Part A focuses on dose escalation without randomization, while Part B involves tumor-specific expansion with randomization in a 1:1 ratio. The primary purpose is treatment, and there is no masking involved.
The study began on November 13, 2024, with the latest update submitted on July 7, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
This update could influence Genmab’s stock performance positively, as successful outcomes may enhance investor confidence and market position. Competitors in the oncology space will be closely monitoring these developments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.